Ulcerative colitis

Ulcerative colitis is an inflammatory disease of the colon and the prevalent opinion states that an inflammation of the upper section of the colon’s mucosal wall is the cause for the disease. Accordingly, current treatment strategies like aminosalycilates (5-ASAs), steroids, immuno-suppressants and biologicals target the inflammatory cascade to prevent further damage to the mucosal cells and to normalize the function of the colon. However, induction and maintenance of symptom remission is not always achieved with current therapies as these approaches do not deal with the underlying cause in the pathology of Ulcerative Colitis as found by Prof. Stremmel: a disturbed mucosal barrier of the colon lining with significant deficits in Phosphatidylcholine. This new finding has opened up a yet unexplored new treatment paradigm which was exploited by Prof. Stremmel in three clinical trials leading to impressive therapeutic effects with no or minimal side effects.